Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomised, Placebo-controlled, Double-blind, Multi-centre, Clinical Trial to Determine the Efficacy and Safety of Presendin in Idiopathic Intracranial Hypertension

NCT05347147 is registered in ClinicalTrials.gov with Invex Therapeutics Ltd. as lead sponsor.

NCT NCT05347147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05347147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomised, Placebo-controlled, Double-blind, Multi-centre, Clinical Trial to Determine the Efficacy and Safety of Presendin in Idiopathic Intracranial Hypertension
Lead sponsor
Invex Therapeutics Ltd.
Phase
Phase 3
Overall status
Terminated
Start date
November 18, 2022
Completion date
October 20, 2023
Enrollment
14 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic intracranial hypertension